Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

Opioid Use Disorder Clinical Trial

Official title:

Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06160284
• Other study ID #: 2000036178
• Secondary ID: P30DA046345
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: July 2024
• Est. completion date: January 2027

Study information

• Verified date: March 2024
• Source: Yale University
• Contact: Gustavo Angarita, MD, MHS
• Phone: (203) 974-7536
• Email: gustavo.angarita[@]yale.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will examine the synaptotrophic effects of psilocybin among medically healthy, detoxified OUD subjects. Eligible OUD participants will undergo pre- and post- psilocybin administration PET scans with the [11C]-UCB-J radiotracer while inpatient.

Description:

Participants will undergo screening as outpatients at the Clinical Neuroscience Research Unit (CNRU). Once deemed eligible, OUD subjects will be studied as inpatients. However, they will have the option of scheduling their second [11C]-UCB-J PET as an outpatient (pending these participants' agreement to undergo outpatient visits twice per week to provide urine toxicology to monitor abstinence before PET).

The only portion of the study that will be available as outpatient for OUD subjects will be the 1-2 weeks before the second [11C]-UCB-J PET scan. The subject will still be admitted for 1-2 weeks, which will include: inpatient detoxification, baseline [11C]-UCB-J PET scan, psilocybin administration, and overnight observation after psilocybin administration. However, they may be discharged the day following psilocybin administration and return 2x weekly for urine toxicology testing between discharge and the second [11C]-UCB-J PET to confirm abstinence.

Structural magnetic resonance imaging (MRI) scans will be obtained for anatomical registration/partial volume correction from all subjects. Functional MRI (fMRI) scans will be completed pre- and post-psilocybin administration to evaluate changes in resting state connectivity. All subjects will participate in a battery of behavioral assessments for exploratory correlations with [11C]-UCB-J. Inpatient subjects who smoke cigarettes will have the option of using nicotine gum and/or nicotine patch while on the unit in order to prevent or minimize nicotine withdrawal. The [11C]-UCB-J PET scans will be done at the Yale PET Center 1-2 weeks before (baseline) and after psilocybin administration.

This is a single-center study at Yale, that will have study activities completed at the following areas:

• Clinical Neuroscience Research Unit (CNRU) of the Connecticut Mental Health Center (CMHC)

• Yale Positron Emission Tomography (PET) Imaging Center

• Yale Magnetic Resonance Research Center (MRRC)

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 12
• Est. completion date: January 2027
• Est. primary completion date: January 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 55 Years

Eligibility

Inclusion Criteria:

• Voluntary, written, informed consent;

• Physically healthy by medical history, physical, neurological, ECG, and laboratory examinations;

• DSM-5 criteria for Opioid Use Disorder;

• Documented evidence (by urine toxicology) of opioid use (upon screening);

• Inpatient verified > 1 week of abstinence;

• For females, a negative serum pregnancy (beta-HCG) test.

Exclusion Criteria:

• DSM-5 criteria for other substance use disorders (e.g., alcohol, cocaine, sedative hypnotics), except for nicotine (concurrent alcohol or drug use is allowed if it does not meet criteria for a substance use disorder and does not take place during inpatient stay)

• A primary DSM-5 Axis I diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or major depression, as determined by psychiatric history (Mini International Neuropsychiatric Interview, MINI), or another disorder that may interfere with the study's primary outcomes in the view of PI

• Immediate (first-degree relative) family history of formally diagnosed schizophrenia or other psychotic disorders (e.g., delusional disorder, schizoaffective disorder), or bipolar I/II disorder

• A history of significant and/or uncontrolled medical or neurological illness

• Hypertension at screening defined as: systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg;

• History of cardiovascular disease, including but not limited to clinically significant coronary artery disease, cardiac hypertrophy, cardiac ischemia, congestive heart failure, myocardial infarction, angina pectoris, coronary artery bypass graft or artificial heart valve, stroke, transient ischemic attack, or any clinically significant arrhythmia

• Any clinically significant abnormal electrocardiogram (ECG) finding, such as findings suggestive of ischemia or infarct, complete bundle branch block, atrial fibrillation or other symptomatic arrhythmia, or predominantly non-sinus rhythm, at screening

• Resting QT interval with Fridericia's correction (QTcF) = 450 msec (male) or = 470 msec (female) at Screening, or inability to determine QTcF interval

• Presence of risk factors for torsades de pointes, including: long QT syndrome, uncontrolled hypokalemia or hypomagnesemia, history of cardiac failure, history of clinically significant/symptomatic bradycardia, family history of idiopathic sudden death or congenital long QT syndrome, or concomitant use of a torsadogenic medication

• Current use of psychotropic and/or potentially psychoactive prescription medications considered to the investigators are likely to interfere clinically with human subject's safety (i.e., contraindicated drug-drug interactions with psilocybin) or scientifically (i.e., likely to influence or alter outcomes of the study)

• Medical contraindications to MRI procedures (e.g., ferromagnetic implants/foreign bodies, claustrophobia, etc.)

• Arterial Line Exclusion: Blood donation within eight weeks of the start of the study

• Arterial Line Exclusion: History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto)

• Participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits followed by the Yale PET Center (21CFR361.1).

Related Conditions & MeSH terms

• Opioid Use Disorder
• Opioid-Related Disorders
• Substance-Related Disorders

Intervention

Drug:
• Psilocybin
Participants will receive a single dose of psilocybin administered in 20 mg or 25 mg doses depending on the participant's weight: 20 mg (among participants < 70 kg) or 25 mg (among participants >70 kg). Participants will be administered psilocybin at CNRU, within 1-2 weeks of the baseline [11C]-UCB-J PET.

Locations

Country	Name	City	State
United States	Yale University	New Haven	Connecticut

Sponsors (2)

Lead Sponsor	Collaborator
Yale University	National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Synaptic Density	Change in synaptic density pre- and post- psilocybin administration will be measured using [11C]-UCB-J PET (volume of distribution [VT] and binding potential [BPND]) among OUD. The regions of interest (ROI) will be subregions of the prefrontal cortex identified by preclinical and preliminary clinical studies.	baseline and 1-2 weeks post treatment
Primary	Association between VT and BPND	Association between VT and BPND assessed to determine whether changes in VT are associated with changes in BPND.	up to 12 weeks
Primary	Time to relapse	Mean number of days to relapse assessed by self- report	up to 12 weeks
Primary	Urine toxicology post treatment	The mean number of positive urine tests post treatment will be assessed. Urine samples will be tested for the presence of opioids. A positive test indicates opioid usage in the last 2 weeks.	up to 12 weeks
Secondary	Change in vital signs- heart rate (HR)	Mean change in heart rate measured in beats per minute during Psilocybin session	immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
Secondary	Change in vital signs- respiratory rate (RR)	Mean change in respiratory rate measured in breaths per minute during Psilocybin session	immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
Secondary	Change in vital signs- oxygen saturation	Mean change in percent oxygen saturation assessed using a pulse oximeter during Psilocybin session	immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
Secondary	Change in vital signs- systolic blood pressure	Mean change in systolic blood pressure in mmHg during Psilocybin session	immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
Secondary	Change in vital signs- diastolic blood pressure	Mean change in diastolic blood pressure in mmHg during Psilocybin session	immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
Secondary	Change in vital signs- body temperature	Mean change in body temperature in degrees Fahrenheit during Psilocybin session	immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
Secondary	Total number of participants with treatment emergent adverse events	Total number of participants with any treatment emergent adverse events while on study assessed using the Systematic Assessment for Treatment Emergent Events (SAFTEE).	up to 12 weeks
Secondary	Change in Profile of Mood States (POMS) Score	POMS is a validated 30 item questionnaire used to assess an individual's mood states. Total scores range from 0 to 120 with lower scores indicating a better mood state.	approximately 30 and 150 minutes post Psilocybin treatment
Secondary	Change in Clinical Opioid Withdrawal Scale (COWS) Score	COWS is an 11-item scale to rate common signs and symptoms of opiate withdrawal and monitor these symptoms over time. The summed score determines the stage/severity of opiate withdrawal and assess the level of physical dependence on opioids. Score: 5- 12 = mild; 13-24 = moderate; 25-36 = moderately severe; more than 36 = severe withdrawal	approximately 30 and 150 minutes post Psilocybin treatment
Secondary	Change in Subjective Opioid Withdrawal Scale (SOWS) Score	SOWS is a self-administered scale for opioid withdrawal symptoms. It has16 symptoms whose intensity is rated on a scale of 0 (not at all) to 4 (extremely). Mild Withdrawal = score of 1-10, Moderate withdrawal = 11-20, Severe withdrawal = 21-30	approximately 30 and 150 minutes post Psilocybin treatment
Secondary	Change in Opioid Symptom Checklist (OSC)	The OSC is a 13-item opioid symptom checklist consisting of true/false questions designed to measure opioid effects (e.g., "My skin is itchy"). True scores are totaled up to acute opiate positive and negative symptoms and low true scores will mean not feeling any of the negative and positive symptoms.	approximately 30 and 150 minutes post Psilocybin treatment